A Study to Evaluate Safety and Efficacy of Multiple Dosing With VB10.NEO and Bempegaldesleukin (NKTR-214) Immunotherapy in Patients With Locally Advanced or Metastatic Cancer

Phase 1/2 Completed 41 enrolled Nykode Therapeutics ASA Nektar Therapeutics · collab Vaccibody AS · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This open labelled first in human dose phase 1/2a study is designed to evaluate safety, feasibility and efficacy of multiple dosing with individualised VB10.NEO and bempegaldesleukin (NKTR-214) immunotherapy in patients with locally advanced or metastatic solid tumours.

Timeline

Start: 2018-04-04
Primary completion: 2023-01-30
Completion: 2023-01-30

Publications

Srikrishna D, Sachsenmeier K. We need to bring R0 < 1 to treat cancer too. Genome Med. 2021 Jul 26;13(1):120. doi: 10.1186/s13073-021-00940-9.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Atezolizumab	Monoclonal antibody	—	—
Subject	Bempegaldesleukin	Protein / enzyme biologic	0.006 mg/kg	Intravenous

Indications

No indication recorded.